Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
European Journal of Cancer (Oxford, England : 1990)|May 15, 2019
Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantationGuillaume Manson, Jean-Baptiste Mear, Charles Herbaux, et al.
Cancer Discovery|September 20, 2018
Intertumoral Heterogeneity in SCLC Is Influenced by the Cell Type of OriginDian Yang, Sarah K Denny, Peyton G Greenside, et al.
Nature Communications|April 7, 2021
Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypesChristina M Bebber, Emily S Thomas, Jenny Stroh, et al.
Molecular Cancer Research : MCR|August 13, 2016
Ercc1 Deficiency Promotes Tumorigenesis and Increases Cisplatin Sensitivity in a Tp53 Context-Specific MannerMladen Jokić, Ignacija Vlašić, Miriam Rinneburger, et al.
Journal of Cancer Research and Clinical Oncology|November 14, 2024
A novel mouse model recapitulating the MMR-defective SCLC subtype uncovers an actionable sensitivity to immune checkpoint blockadeOlta Ibruli, France Rose, Filippo Beleggia, et al.
Cancer Research|August 10, 2017
ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA DamageLukas Perkhofer, Anna Schmitt, Maria Carolina Romero Carrasco, et al.
Hematological Oncology|July 5, 2022
Isolated intraocular relapses of primary cerebral lymphomas: An LOC network studyNadia Younan, Carole Soussain, Sylvain Choquet, et al.
Cell Reports|October 26, 2018
The Cdkn1a<sup>SUPER</sup> Mouse as a Tool to Study p53-Mediated Tumor SuppressionAlessandro Torgovnick, Jan Michel Heger, Vasiliki Liaki, et al.
Cell|July 4, 2015
A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant CancerFelix Dietlein, Bastian Kalb, Mladen Jokic, et al.
Pageof 6